search
Back to results

Adult Respiratory Failure Intervention Study Africa (ARISE-AFRICA)

Primary Purpose

Acute Respiratory Failure With Hypoxia, Acute Respiratory Distress Syndrome, Acute Lung Injury

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
HFNC
CPAP
Standard Oxygen
Sponsored by
Makerere University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acute Respiratory Failure With Hypoxia

Eligibility Criteria

18 Years - 95 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • De novo acute respiratory distress, as defined by dyspnea, use of accessory respiratory muscles, and a respiratory rate of 25 breaths per minute or more,
  • Hypoxemia, as defined by a ratio of the partial pressure of arterial oxygen (PaO2) to the fraction of inspired oxygen (FiO2) of less than 300 mm Hg or a oxygen saturation by pulse oximetry SpO2/FiO2 ratio <315 will be considered for inclusion
  • Informed consent obtained in accordance with local regulations;

Exclusion Criteria:

  • Exacerbation of asthma, chronic obstructive pulmonary disease or another known or suspected chronic respiratory disease;
  • Absolute contraindications to CPAP or HFNC
  • Cardiac arrest; severe ventricular arrhythmia; shock defined by the need for vasopressors (dopamine > 5 microg/kg/min or adrenaline or noradrenaline at any dose)
  • Altered consciousness (Coma Glasgow Score below 12 points);
  • Do not intubate order, do not resuscitate order, or decision to limit full care taken before obtaining informed consent;
  • Refusal to participate, prior enrolment in the trial, participation in another interventional study on respiratory distress;

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    Experimental

    Experimental

    Active Comparator

    Arm Label

    High-flow oxygen nasal cannula (HFNC)

    Continuous positive airway pressure (CPAP)

    Standard Low flow Oxygen Arm

    Arm Description

    In the high-flow-nasal cannula group, oxygen will be delivered through a heated humidifier and applied continuously through large-bore bi-nasal prongs, with a gas flow rate of 40-60 liters per minute and adjusted based on the clinical response.

    Patients assigned to the CPAP plus oxygen group will receive periods of CPAP in addition to the standard treatment. CPAP will be started at 7.5 cm of water. The level will be decreased to 5 cm of water or increased to 10 cm of water as needed based on the clinical response and tolerance.

    Patients assigned to the standard treatment group will receive oxygen delivered through a Non-rebreather face mask until endotracheal intubation, death, or fulfillment of oxygen delivery cessation criteria (an oxygen saturation by pulse oximetry (SpO2) above 92% without oxygen and a respiratory rate below 25 cycles/min).

    Outcomes

    Primary Outcome Measures

    Mortality
    Number of study participants deceased at day 28 of study randomisation

    Secondary Outcome Measures

    Number of patients intubated and ventilator-free
    Number of patients intubated and ventilator-free at 28 days from randomisation
    Patient Tolerance to CPAP or HFNC
    Patients will be assessed using the Likert scale
    Organ failure free days
    Number of days from randomisation free of organ failure
    Number of patients who meet criteria for intubation at day 7
    Number of patients who meet criteria for intubation at day 7 of randomisation

    Full Information

    First Posted
    December 6, 2020
    Last Updated
    March 10, 2023
    Sponsor
    Makerere University
    Collaborators
    THRiVE, Paris 12 Val de Marne University, Wellcome Trust
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04693403
    Brief Title
    Adult Respiratory Failure Intervention Study Africa
    Acronym
    ARISE-AFRICA
    Official Title
    A Multicentre, Randomized, Clinical Trial of Respiratory Support With Standard Low Flow Oxygen Therapy, Continuous Positive Airway Pressure, and High-flow Oxygen Therapy in Adults With Acute Hypoxemic Respiratory Failure in Uganda
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    March 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    March 2023 (Anticipated)
    Primary Completion Date
    September 2023 (Anticipated)
    Study Completion Date
    November 2023 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Makerere University
    Collaborators
    THRiVE, Paris 12 Val de Marne University, Wellcome Trust

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Product Manufactured in and Exported from the U.S.
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    The dearth of Intensive care units in low resource settings portends for poor outcomes amongst patients with acute hypoxemic respiratory failure (AHRF) . To our knowledge, the effect of CPAP and HFNC on major outcomes has not been assessed in adults with AHRF in resource-limited settings. The aim of this prospective, multicenter, randomized, controlled, trial is to determine whether High-flow oxygen through a nasal cannula (HFNC) or Continuous positive airway pressure (CPAP) system can reduce mortality among patients with acute hypoxemic respiratory failure (AHRF) in a limited resource setting as compared with standard low flow oxygen therapy?
    Detailed Description
    The care for the critically ill patient typically takes place in the intensive care unit (ICU). ICU care is quite expensive, even in resource rich countries. The most common reason for ICU admission globally is respiratory support for acute hypoxemic respiratory failure (AHRF). In patients with AHRF, the need for invasive mechanical ventilation is associated with high mortality, especially in low income countries (LICs), given the scarce availability of invasive mechanical ventilation. Some studies suggest that administration of ventilatory support through a mask may be effective in resource-limited settings. However, there is no clinical study data in adults to support this evidence. Human and material constraints are major barriers for the care of critically-ill patients in resource limited settings , advocating the need for a frugal approach. Furthermore, the scarcity of intensive care unit care in LICs contributes to a high mortality among acutely ill patients. The current corona virus pandemic has further highlighted the need for frugal acute care interventions in LICs. Continuous positive airway pressure (CPAP) is a simple to use and affordable technique for noninvasive ventilatory support. High-flow oxygen through a nasal cannula (HFNC) may also offer an alternative in patients with hypoxemia. The high flow rates may also decrease physiological dead space by flushing expired carbon dioxide from the upper airway, a process that potentially explains the observed decrease in the work of breathing. Frugal CPAP or HFNC , as compared with standard oxygen therapy, could reduce the mortality among adults presenting with AHRF in a resource-limited setting.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Acute Respiratory Failure With Hypoxia, Acute Respiratory Distress Syndrome, Acute Lung Injury

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Model Description
    Stepped wedge cluster randomised trial (8 Clusters).
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    504 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    High-flow oxygen nasal cannula (HFNC)
    Arm Type
    Experimental
    Arm Description
    In the high-flow-nasal cannula group, oxygen will be delivered through a heated humidifier and applied continuously through large-bore bi-nasal prongs, with a gas flow rate of 40-60 liters per minute and adjusted based on the clinical response.
    Arm Title
    Continuous positive airway pressure (CPAP)
    Arm Type
    Experimental
    Arm Description
    Patients assigned to the CPAP plus oxygen group will receive periods of CPAP in addition to the standard treatment. CPAP will be started at 7.5 cm of water. The level will be decreased to 5 cm of water or increased to 10 cm of water as needed based on the clinical response and tolerance.
    Arm Title
    Standard Low flow Oxygen Arm
    Arm Type
    Active Comparator
    Arm Description
    Patients assigned to the standard treatment group will receive oxygen delivered through a Non-rebreather face mask until endotracheal intubation, death, or fulfillment of oxygen delivery cessation criteria (an oxygen saturation by pulse oximetry (SpO2) above 92% without oxygen and a respiratory rate below 25 cycles/min).
    Intervention Type
    Procedure
    Intervention Name(s)
    HFNC
    Other Intervention Name(s)
    High-flow oxygen by nasal cannula
    Intervention Description
    40-60l/min humidified oxygen by nasal cannula
    Intervention Type
    Procedure
    Intervention Name(s)
    CPAP
    Other Intervention Name(s)
    Continuous positive airway pressure
    Intervention Description
    Oxygen therapy by boussignac Continuous positive airway pressure face mask
    Intervention Type
    Procedure
    Intervention Name(s)
    Standard Oxygen
    Other Intervention Name(s)
    Standard Oxygen Therapy (low flow)
    Intervention Description
    Oxygen therapy by low flow (upto 15l/min) by Non-rebreather face mask
    Primary Outcome Measure Information:
    Title
    Mortality
    Description
    Number of study participants deceased at day 28 of study randomisation
    Time Frame
    28 day
    Secondary Outcome Measure Information:
    Title
    Number of patients intubated and ventilator-free
    Description
    Number of patients intubated and ventilator-free at 28 days from randomisation
    Time Frame
    28 days
    Title
    Patient Tolerance to CPAP or HFNC
    Description
    Patients will be assessed using the Likert scale
    Time Frame
    7 days
    Title
    Organ failure free days
    Description
    Number of days from randomisation free of organ failure
    Time Frame
    7 days
    Title
    Number of patients who meet criteria for intubation at day 7
    Description
    Number of patients who meet criteria for intubation at day 7 of randomisation
    Time Frame
    7 days

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    95 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: De novo acute respiratory distress, as defined by dyspnea, use of accessory respiratory muscles, and a respiratory rate of 25 breaths per minute or more, Hypoxemia, as defined by a ratio of the partial pressure of arterial oxygen (PaO2) to the fraction of inspired oxygen (FiO2) of less than 300 mm Hg or a oxygen saturation by pulse oximetry SpO2/FiO2 ratio <315 will be considered for inclusion Informed consent obtained in accordance with local regulations; Exclusion Criteria: Exacerbation of asthma, chronic obstructive pulmonary disease or another known or suspected chronic respiratory disease; Absolute contraindications to CPAP or HFNC Cardiac arrest; severe ventricular arrhythmia; shock defined by the need for vasopressors (dopamine > 5 microg/kg/min or adrenaline or noradrenaline at any dose) Altered consciousness (Coma Glasgow Score below 12 points); Do not intubate order, do not resuscitate order, or decision to limit full care taken before obtaining informed consent; Refusal to participate, prior enrolment in the trial, participation in another interventional study on respiratory distress;
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Daphne Kabatooro, MD
    Phone
    +256774620752
    Email
    karudaph@gmail.com
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Arthur Kwizera, MD
    Organizational Affiliation
    Makerere University
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    Yes
    IPD Sharing Plan Description
    De-identified data, upon reasonable request.
    IPD Sharing Time Frame
    Upon study completion, in perpetuity.
    IPD Sharing Access Criteria
    By email.

    Learn more about this trial

    Adult Respiratory Failure Intervention Study Africa

    We'll reach out to this number within 24 hrs